Skip to main content

Venous Insufficiency

1
Pipeline Programs
6
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
Venocur Triplex®Phase 41 trial
Active Trials
NCT00835822Completed216
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
7 programs
Antistax®PHASE_21 trial
Antistax®, low dosePHASE_21 trial
Antistax®PHASE_31 trial
BNS003PHASE_31 trial
Read vine leaf extractPHASE_31 trial
+2 more programs
Active Trials
NCT02191163Completed71
NCT02191280Completed260
NCT02191254Completed245
+4 more trials
Echosens
EchosensFrance - Paris
1 program
CutometerN/A1 trial
Active Trials
NCT02061254Completed130Est. Jun 2015
Smith and Nephew
Smith and NephewMA - Andover
1 program
PICO TreatmentN/A1 trial
Active Trials
NCT06510777Terminated142Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottVenocur Triplex®
Boehringer IngelheimAntistax film coated tablets
Boehringer IngelheimRed vine leaf extract
Boehringer IngelheimRead vine leaf extract
Boehringer IngelheimBNS003
Boehringer IngelheimAntistax®
Boehringer IngelheimAntistax®
Boehringer IngelheimAntistax®, low dose
Smith and NephewPICO Treatment
EchosensCutometer

Clinical Trials (10)

Total enrollment: 1,761 patients across 10 trials

NCT00835822AbbottVenocur Triplex®

Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency

Start: May 2005216 patients
Phase 4Completed
NCT02184234Boehringer IngelheimAntistax film coated tablets

Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)

Start: Jun 200165 patients
Phase 4Completed
NCT00855179Boehringer IngelheimRed vine leaf extract

Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency

Start: Mar 2009250 patients
Phase 3Completed
NCT00292435Boehringer IngelheimRead vine leaf extract

Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)

Start: Mar 2006202 patients
Phase 3Completed
NCT02211898Boehringer IngelheimBNS003

Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux

Start: Jul 2004180 patients
Phase 3Completed
NCT02191254Boehringer IngelheimAntistax®

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

Start: Apr 2004245 patients
Phase 3Completed
NCT02191163Boehringer IngelheimAntistax®

Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency

Start: Apr 200271 patients
Phase 2Completed
NCT02191280Boehringer IngelheimAntistax®, low dose

Antistax® in Patients With Chronic Venous Insufficiency

Start: Apr 1998260 patients
Phase 2Completed
NCT06510777Smith and NephewPICO Treatment

PICO Venous Leg Ulcers (VLU) Reimbursement Study

Start: Dec 2023Est. completion: Oct 2025142 patients
N/ATerminated
NCT02061254EchosensCutometer

Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)

Start: Apr 2014Est. completion: Jun 2015130 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.